Efficacy of 0.5 mg Dienogest Tablets in Treating Premenstrual Syndrome-like Symptoms: A Comparative Study with a Low-Dose Estrogen–Progestin Combination
This study found that 0.5 mg dienogest tablets administered twice daily significantly improved premenstrual syndrome-like symptoms compared to a low-dose estrogen–progestin combination over six months.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
My notes (saved in your browser only)
Condition tags
Citation neighborhood
Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.
References (27)
- A progestin isn’t a progestin: dienogest for endometriosis as a blueprint for future research – Review as a contribution for discussion - via openalex
- Dienogest, a selective progestin, reduces plasma estradiol level through induction of apoptosis of granulosa cells in the ovarian dominant follicle without follicle-stimulating hormone suppression in monkeys via openalex
- Evaluation of the efficacy, safety, and clinically recommended dose of dienogest in the treatment of primary dysmenorrhea: a randomized, double-blind, multicenter, placebo-controlled study via openalex
- Impact of 1.0 mg/Day Dienogest Treatment on Bone Metabolism Markers in Young Women with Dysmenorrhea via openalex
- Long‐term use of dienogest for the treatment of primary and secondary dysmenorrhea via openalex
- Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial via openalex
- Ovulation‐Inhibiting Effects of Dienogest in a Randomized, Dose‐Controlled Pharmacodynamic Trial of Healthy Women via openalex
- The effects of dienogest and combined oral contraceptives on protein S-specific activity in endometriosis patients via openalex
- doi:10.1111/j.1447-0578.2007.00189.x via openalex
- doi:10.1007/s00737-012-0266-2 via openalex
- doi:10.1016/j.ajog.2006.05.012 via openalex
- doi:10.1007/s00737-006-0137-9 via openalex
- doi:10.1530/jrf.0.0490189 via openalex
- doi:10.2147/ijwh.s242864 via openalex
- doi:10.1111/jog.15950 via openalex
- doi:10.1016/j.ogrm.2016.11.003 via openalex
- doi:10.1097/aog.0000000000005426 via openalex
- doi:10.1080/09513590.2017.1423466 via openalex
- doi:10.1016/j.ajog.2004.12.089 via openalex
- doi:10.1111/cen.13932 via openalex
- doi:10.1080/13697130500148875 via openalex
- doi:10.3109/13625187.2012.677076 via openalex
- doi:10.1186/s13030-021-00208-z via openalex
- doi:10.1111/j.1447-0756.2007.00581.x via openalex
- doi:10.1177/070674370505000607 via openalex
- doi:10.1016/0022-4731(81)90362-9 via openalex
- doi:10.1136/bmj.323.7316.776 via openalex
Cited by (1)
Source provenance
- openalex
- last seen: 2026-05-14T06:15:02.999540+00:00